The Food and Drug Administration today said it no longer authorizes the use of hydroxychloroquine or chloroquine as an effective treatment of COVID-19.

FDA cited serious side effects, such as cardiac adverse events, in its decision, stating that it considered results from a large trial and found neither drug to “be effective in treating COVID-19, nor is it reasonable to believe that the known and potential benefits of these products outweigh their known and potential risks.” FDA said patients who have already been administered the drugs that were distributed under the original emergency use authorization may continue their use if deemed necessary by physicians.

Related News Articles

Blog
The American Hospital Association and its Society for Healthcare Strategy and Market Development (SHSMD) July 15 hosted “Addressing COVID-19 Vaccine Hesitancy…
Headline
Read a recap and insights from health care leaders during AHA’s July 15 webinar, “Addressing COVID-19 Vaccine Hesitancy in Your Community,” featuring messaging…
Headline
Three-quarters of the 469 COVID-19 cases associated with summer events and large public gatherings this month in Barnstable County, Mass., were in people fully…
Headline
About 8.9 million children aged 12-17 have received the Pfizer COVID-19 vaccine, the Centers for Disease Control and Prevention reported today. Based on data…
Headline
AHA today joined 27 other organizations that serve the mental, emotional and behavioral health of children in urging Congress to strengthen the pediatric…
Perspective
The COVID-19 Provider Relief Fund has been a lifeline for hospitals, health systems and health care providers, allowing them to continue to put the health and…